Graham Beaton

Title: Graham Beaton: Innovator in Nucleic Acid Therapeutics

Introduction

Graham Beaton is a notable inventor based in Boulder, CO (US). He has made significant contributions to the field of nucleic acid therapeutics and diagnostics. His innovative work focuses on the development of modified oligonucleotides that enhance the efficacy of nucleic acid-based treatments.

Latest Patents

Graham Beaton holds a patent for "Modified oligonucleotides and intermediates useful in nucleic acid." This invention provides nuclease-resistant 3'-carbon modified oligonucleotides that can be utilized in nucleic acid therapeutics and diagnostics. The modified oligonucleotides feature at least one modified internucleotide linkage, where the divalent oxygen moiety at the 3'-position is replaced by a tetravalent carbon moiety. The preferred linkages are 3'-methylene or 3'-hydroxymethylene. Additionally, the patent includes methods and monomeric nucleoside and nucleotide intermediates for creating these modified oligonucleotides.

Career Highlights

Graham Beaton is currently associated with Amgen Inc., a leading biotechnology company. His work at Amgen has allowed him to further his research and development in the field of nucleic acids. He has demonstrated a commitment to advancing therapeutic options through innovative scientific approaches.

Collaborations

Graham collaborates with Eric F Fisher, contributing to the advancement of their shared research interests. Their partnership exemplifies the collaborative spirit often found in scientific research, leading to groundbreaking innovations.

Conclusion

Graham Beaton's contributions to the field of nucleic acid therapeutics through his patented innovations highlight his role as a significant inventor. His work continues to pave the way for advancements in medical science and therapeutic applications.